Beyond the counter: Navigating the landscape of Deanxit® dispensing - Insights from Jordanian community pharmacies.

Background: This study investigates the dispensing patterns and knowledge of community pharmacists regarding Deanxit®, a combination of melitracen and flupentixol approved for the treatment of depression and anxiety in Jordan. Methods: This study employed a mixed-methods approach, involving 75 randomly selected pharmacies in two Jordanian governorates (Amman and Irbid). The investigation involved simulated patient scenarios and structured interviews employing a validated tool. Results: The analysis revealed that 70.6% of pharmacists were willing to dispense Deanxit® based on simulated scenarios, indicating malpractice. The mean practice score was 0.5867 out of 18, underlining a substantial level of malpractice. Pharmacists demonstrated poor knowledge, with a median score of 2.0 out of 15, reflecting a lack of awareness about Deanxit's labeled indications. Furthermore, 96% reported dispensing without prescriptions, and 62.1% acknowledged encountering cases of improper Deanxit® use. Conclusion: This study provides valuable insights into the current landscape of Deanxit® dispensing patterns, pharmacists' poor knowledge levels, and malpractices in Jordan. By identifying areas for improvement and offering recommendations for intervention, this study contributes to enhancing pharmacy practice and patient care outcomes in the region.

Melitracen and flupentixol (deanxit) use disorder in Lebanon.

Introduction: Deanxit is a combination of melitracen and flupentixol, not approved as an antidepressant for sale and use in several countries but still widely available and commonly used among the Lebanese population. The study aimed to assess Deanxit use disorder, assess the source of the medication, and the consumers' awareness of the therapeutic and side effects of Deanxit, among the Lebanese population. Methods: This is a cross-sectional study that included all patients taking Deanxit and visited the Emergency Department between October 2019 and October 2020. All patients who agreed to participate in the research through written consent forms were contacted by telephone and a questionnaire was filled out. Results: A total of 125 patients taking Deanxit were included in the study. According to the DSM-V criteria, 36% (n = 45) had a Deanxit use disorder. Most of the participants were females (n = 99, 79.2%), married (n = 90, 72%), and between the ages of 40-65 years (n = 71, 56.8%). Most patients (n = 41, 91%) had Deanxit prescribed by a physician for anxiety (n = 28, 62%), and obtained it using a prescription (n = 41, 91%). Almost half of all patients (n = 60, 48%) did not have sufficient knowledge of the reason it was prescribed, 54.4% (n = 68) were not sure they are taking the medication appropriately, and 19.2% (n = 23) were satisfied by the overall explanation of the physicians concerning Deanxit use. Conclusion: Deanxit use disorder is underrecognized among Lebanese patients. Most of our patients were prescribed Deanxit by their physicians but reported inadequate knowledge of its side effects and risk of abuse.

Deanxit and tandospirone relieved unexplained limb edema in a depressed pituitary adenoma survivor: A case report.

Our case report describes a 45-year-old woman who suffered from limb edema for 2 months. We focused on tumor recurrence and other common potential diseases based on the pituitary adenoma history. However, none of the examinations showed any abnormality. Later, her continuous complaints about the family relationship and depressed mood came into sight, and a psychiatry consultation was arranged. Following that, she was diagnosed with major depressive disorder. After several days of Deanxit and tandospirone treatment, the patient's limb edema dramatically subsided. This is the first case of limb edema associated with depression. This highlights the importance of awareness of mental illness for non-psychiatrists, especially in patients with severe somatic symptoms, but with negative results.

Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A network meta-analysis of randomised controlled trials.

BACKGROUND: Although tinnitus has a prevalence between 20 and 42.8%, the currently recommended management for tinnitus, such as tinnitus support and psychologic therapies, are relatively time-consuming and expensive. Several new pharmacologic treatments designed for tinnitus patients without specific origin had been developed but their efficacy remains unclear. METHODS: The current Network Meta-Analysis (NMA) of randomised controlled trials (RCTs) was conducted to evaluate the efficacy of different pharmacologic treatments for tinnitus management in tinnitus patients without specific or treatable origin (i.e. primary tinnitus). Databases were searched from inception to April 5th, 2021. All network meta-analytic procedures were conducted under the frequentist model. We calculated the effect size of outcomes with different rating scales with standardized mean difference. PROSPERO registration: CRD42020177742. FINDINGS: Overall, 36 RCTs were included with 2,761 participants. The main results revealed that pharmacologic interventions with brain-acting effect (for example, amitriptyline, acamprosate, and gabapentin) and those with anti-inflammation/anti-oxidant effect (for example, intra-tympanic dexamethasone injection plus oral melatonin) were associated with superior improvement in tinnitus severity and response rate compared to placebo/control. Oral amitriptyline were associated with the highest improvement in tinnitus severity and the fourth highest response rate. None of the investigated interventions was associated with different changes in quality of life compared to placebo/control. All the investigated treatments were associated with similar drop-out rate to placebo/control. INTERPRETATION: The current NMA suggests a potential role for treatments with brain-acting effect (for example, amitriptyline, acamprosate, and gabapentin) or anti-inflammation/anti-oxidant effect (for example, intra-tympanic dexamethasone injection plus oral melatonin) as the preferable effective treatments for tinnitus without specific or treatable origin. FUNDING: none.

Deanxit can improve the dizziness, anxiety, and quality of life of patients with chronic subjective dizziness.

OBJECTIVE: This study was designed to analyze the clinical effectiveness of Deanxit (DEA) for treating chronic subjective dizziness (CSD). METHODS: A total of 110 CSD patients (all from a community survey) admitted to our hospital from August 2018 to August 2020 were recruited as the study cohort. Among them, 60 who underwent DEA treatment were placed in the research group (RG) and 50 who underwent basic treatment were placed in the control group (CG). The two groups' efficacy, their dizziness disability rating scale (DHI) scores, the improvement in their clinical symptoms (duration of dizziness, frequency of dizziness attacks), their anxiety and depression (i.e., their Hamilton Anxiety Scale (HAMA) scores) and their Hamilton Depression Scale (HAMD)) scores, their sleep quality and their quality of life (short form 36 (SF-36) health survey scores) were observed and compared. RESULTS: Compared with the CG, the DHI scores, the dizziness durations, the number of dizziness attacks and the HAMA and HAMD scores in the RG were markedly lower than they were in the CG, and the sleep quality levels and SF-36 scores were higher than they were in the CG. CONCLUSION: DEA treatment helps to improve the dizziness, anxiety, and quality of life of CSD patients.

[Effect analysis on Deanxit combined with Shuganjieyu capsule in the treatment of refractory gastroesophageal reflux disease].

Objective: To investigate the curative effect of Deanxit combined with Shuganjieyu capsule on the treatment of refractory gastroesophageal reflux disease. Methods: A total of 125 patients with refractory gastroesophageal reflux disease who had failed in standard lansolazole capsule treatment in the Department of Gastroenterology, First People's Hospital of Neijiang were selected. According to the symptom scores and mood scores of gastroesophageal reflux disease, patients were randomly and double-blindly divided into five groups. Group A(Lansoprazole Capsules + Mosapride Citrate + Deanxit), B(Lansoprazole Capsules + Mosapride Citrate + Shuganjieyu capsule), C(Lansoprazole Capsules + Mosapride Citrate+ Deanxit + Shuganjieyu capsule) and D(Deanxit) groups are study groups, the other was control group (Lansoprazole Capsules + Mosapride Citrate). The scores of symptoms and mood were compared after 4 weeks and 8 weeks of treatment. Results: The clinical symptoms score, HAMA and HAMD scores were significantly lower in the all study groups in comparison to the control group after 4 weeks and 8 weeks therapy. The clinical symptoms score, HAMA and HAMD scores in group C were significantly lower than those in group A and B (P<0.05), while the difference between group A and B was not statistically significant(P>0.05). The HAMA and HAMD scores of group D were significantly higher than those of group A, B, C and control group, and the differences were statistically significant (P<0.05). The total effective rate of study groups were significantly higher than those of the control group, and the difference was statistically significant (P<0.05). The total effective rate of group C was significantly higher than that of group A and B (χ(2)=6.47, P<0.05). The total effective rate of group A at the end of the 8th week was significantly higher than that of group B (χ(2)=6.52, P<0.05). The total effective rate of group D at the end of the 4th and 8th week was significantly lower than those of the group A, B, C and control group, the difference was statistically significant (χ(2)=5.85, P<0.05). Conclusions: Deanxit combined with Shuganjieyu capsule is significantly effective in treatment of refractory gastroesophageal reflux disease, which can effectively improve the total treatment efficiency, reduce the symptom scores and mood scores of gastroesophageal reflux disease patients.

Deanxit relieves symptoms in a patient with jackhammer esophagus: A case report.

Jackhammer (hypercontractile) esophagus presents with dysphagia and chest pain. Current treatments are limited. We describe a 60-year-old man who presented with dysphagia, chest pain and heartburn for a period of 1 year. His workup showed Barrett's esophagus on endoscopy and high-resolution manometry demonstrated jackhammer esophagus with esophagogastric junction outflow obstruction. The patient was treated with proton pump inhibitor and nifedipine but without resolution of his symptoms. He was followed up to assess the efficacy of treatment with deanxit (flupentixol + melitracen). Dysphagia and chest pain resolved during the therapeutic trial and efficacy was maintained on maintenance treatment without troublesome side effects.

Clinical Observation of Plum-blossom Needling Combined with Deanxit for Treatment of Depression or Anxiety in Chronic Tension Headache Patients / 广州中医药大学学报

Objective To observe the clinical efficacy of plum-blossom needling combined with Deanxit for the treatment of depression or anxiety in chronic tension headache patients. Methods Sixty chronic tension headache patients with depression and/or anxiety were randomized into treatment group and control group , 30 cases in each group. The treatment group was treated by plum-blossom needling combined with oral use of Deanxit , and the control group was treated only by oral use of Deanxit. After treatment for 4 weeks , the scores of headache symptom, Hamilton Depressive Scale (HAMD), and Hamilton Anxiety Scale (HAMA) of the two groups were observed. Results After treatment , the scores of headache symptom , HAMA and HAMD in all patients were decreased (P < 0 . 05 compared with those before treatment), and the decrease in the treatment group was obviously superior to that in the control group, the difference being significant between the two groups (P <0.05). Conclusion Plum-blossom needling combined with Deanxit shows better effect than Deanxit for the treatment of depression or anxiety in chronic tension headache patients.

Adverse reactions of lansoprazole combined with Flupentixol and melitracen in the treatment of functional dyspepsia patients / 中国生化药物杂志

Objective To analyze the curative effect and adverse reaction of lansoprazole combined with droperidol thiadiazole melitracen treatment in patients with functional dyspepsia.Methods From December 2013 to December 2015 in our hospital and accepted treatment of 90 patients with functional digestive adverse as the research object,according to the random number table were divided into the control group and the observation group,45 cases in each group.The control group by oral administration of lansoprazole enteric coated capsules,the observation group taking oral lansoprazole and droperidol thiadiazole melitracen,course lasted for 4 weeks,efficacy and adverse occurrence was compared between two groups of patients.Results After 4 weeks of treatment,the observation group with symptoms score GSRS(postprandial fullness discomfort,early satiety,abdominal pain,epigastric burning sensation were lower than the control group with postprandial fullness discomfort early satiety,abdominal pain,epigastric burning sensation,and the difference was statistically significant(P<0.05); the patients in the observation group after 4 weeks of treatment,the total effective rate(86.7％)was higher than the control group(66.7％)significantly,and difference was statistically significant(P<0.05); symptoms of adverse reactions of two groups of patients in the process of drug use were mild and did not give special treatment,in a few days after the basic relief.Conclusion Lansoprazole combined with fluorine Pai Sai tons of Murray Song Xin can effectively eliminate or reduce the symptoms of functional dyspepsia patients clinical and no serious adverse reactions,it is safe in clinical application.

Evaluation of anti anxiety treatment in residual dizziness after successful canalith repositioning procedure in benign paroxysmal positional vertigo / 中国基层医药

Objective To study the effect of anti anxiety treatment in residual dizziness after successful canalith repositioning procedure in benign paroxysmal positional vertigo.Methods 68 cases of benign paroxysmal position vertigo patients with residual dizziness after successful canalith repositioning procedure were collected,who visit department of Neurology..They were randomly assigned to anti anxiety group and the control group according to randomized controlled method.Deanxit (0.5mg/10mg,1times/day)combined with betahistine mesilate tablets (6mg, 3 times/day)were taken by patients in the anti anxiety group;take betahistine mesilate tablets (6mg,3 times/day) were taken in the control group.Follow up 3 months,the duration of residual dizziness and the changes of symptoms between the two groups were compared.The symptoms of all patients were evaluated before and after treatment by dizziness handicap inventory.Results The duration of residual dizziness in the control group was (16.38 ±8.83)days, and that in the anti anxiety group was (10.13 ±5.10)days.The duration of residual dizziness in the anti anxiety group was significantly shorter than that in the control group (t =3.440,P 0.05)in the treatment of first week.In second week and third week,the scores of the anti anxiety group were lower than those of the control group,the differences were statistically significant (t =3.378,4.935,all P <0.05).After 3 weeks of treatment,the scores of the anti anxiety group were significantly decreased in the functional,emotional and physical scores (t =5.297,4.537,4.451,all P <0.01 ).Conclusion Deanxit can shorten residual dizziness duration of benign paroxysmal position vertigo patients after successful canalith repositioning procedure,and can reduce the degree of residual dizziness.

Effect of Deanxit in treatment of irritable bowel syndrome on hematological index and intestinal sensitivity / 中国生化药物杂志

Objective To investigate the effect of Deanxit in treatment of Irritable bowel syndrome in patients in hematological index and intestinal sensitivity.Methods 82 cases with Irritable bowel syndrome were selected and divided into two groups, each had 41 cases.Control group was treated with conventional therapy, experiment group was treated on the base of the treatment with Deanxit.Hematology ndex and intestinal sensitivity index and clinical effect were compared after treatment.Results Compared with pre-treatment, plasma SS, SP and 5-HT decreased in two groups after treatment, NPY increased, levels of TNF-α, IL-6 and IL-8 decreased, levels of IL-10 increased, abdominal pain score, abdominal distension and diarrhea score score decreased, the differences were all significant(P<0.05).Compared with control group, plasma SS, SP and 5-HT in the experiment group were lower, NPY was higher, levels of TNF-α, IL-6 and IL-8 were lower, levels of IL-10 were higher, abdominal pain score, abdominal distension and diarrhea score score were lower than control group, the differences were all significant ( P <0.05 ) .Conclusion Deanxit in the treatment of Irritable bowel syndrome has curative effect.

Deanxit combined with large dose of oryzanol in treatment of post stroke depression and anxiety in elderly male / 中国医师进修杂志

Objective To investigate the therapy effect of deanxit combined with large dose of oryzanol in the treatment of post stroke depression(PSD) and anxiety in elderly male.Methods Sixty cases of PSD and anxiety patients were divided into three groups by random number table method with 20 cases in each,deanxit group treated with deanxit,oryzanol group treated with oryzanol,and combination group treated with deanxit and large dose of oryzanol,a total of 4 weeks.Before and after 4 weeks treatment respectively using Hamilton depression scale (HAMD) and Hamilton anxiety scale (HAMA) scores.Results The HAMD and HAMA scores before treatment in three groups had no statistical significance (P ＞ 0.05).Compared with before treatment,HAMD and HAMA scores in three groups after treatment were significantly lower (P＜ 0.01).HAMD scores in combination group were improved better than those in deanxit group and oryzanol group [(12.85 ± 3.69) scores vs.(15.30 ± 3.28),(18.65 ± 3.13) scores](P＜ 0.01),and deanxit group were better than oryzanol group(P＜ 0.01).HAMA scores in deanxit group and combination group were lower than those in oryzanol group [(8.65 ± 3.33),(7.25 ± 3.34) scores vs.(10.65 ± 3.18) scores] (P ＜0.01).Conclusion Deanxit combined with oryzanol is effective in the treatment of PSD and anxiety in elderly male.

Clinical observation of itopride and esomeprazole combining with deanxit in treating functional dyspepsia / 中国基层医药

Objective To investigate the clinical effect of Itopride and esomeprazole combining with deanxit in treating functional dyspepsia ( FD) .Methods Sixty-two patients meeting Rome Ⅲcriterion were randomly divided into the therapy groups which were treated with Itopride and esomeprazole combining with deanxit and the control groups which were treated with Itopride and esomeprazole for 4 weeks respectively .Symptom scoring was done before and after the treatment .Results The symptoms were remarkably improved , there was significant difference in the therapeutic effect between the two groups (P<0.05).The total efficiency was more obvious in the therapy group . Conclusion Itopride and esomeprazole combining with deanxit can produce an effect on the treatment of FD .Itopride and esomeprazole combining with deanxit has better clinical effect than Itopride and esomeprazole on the treatment of FD.

Effects of Deanxit on depression and clinical outcomes in elderly patients with acute coronary syndrome / 中华行为医学与脑科学杂志

Objective To investigate deanxit clinical efficacy of depression in elderly patients with acute coronary syndrome(ACS).Methods 88 elderly patients with ACS and depression were randomly divided into Deanxit (2 tablets daily ; Deanxit,n =43) or placebo (control,n =45) treatment in addition to standard therapy.SDA score,SDS score,MACE and cardiac autonomic nerve function were performed at 12 weeks follow-up.Results In deanxit group,SDA score and SDS score were significantly reduced (34.28 ± 6.35 vs 52.68 ± 5.74,41.19 ±4.63 vs 54.68 ± 4.32,P ＜ 0.05),MACE were also decreased (4.6％ vs 28.9 ％,P ＜ 0.05).SDNN were significantly higher than control (109.03 ± 23.08 vs 98.29 ± 27.44,P ＜ 0.05),but LF was reduced (152.89 ± 92.75vs 249.21 ± 64.17,P＜ 0.05).Conclusion Deanxit can improve the depression and clinical symptoms in elderly patients with ACS and depression.By improving the cardiac autonomic nerve function,deanxit possible reduce the onset of severe arrhythmia and improve the short-term prognosis.

The curative effect of deanxit in adjuvant treatment of 66 patients with irritable bowel syndrome / 中国基层医药

Objective To investigate the effect of deanxit in adjuvant treatment of the patients with irritable bowel syndrome and the psychologicalon of the patients. Methods Clinical data of 66 patients with irritable bowel syndrome were retrospectively analyzed. The control group was treated by conventional therapy, and the observation group was given deanxit based on the treatment of the control group. Then the curative effect were observed. Results In 132 patients,98 cases were troubed with anxiety,9 cases with athymia, the incidence rate was 81%. After treatment the SAS and SDS score of the observation group reduced,compared with before treatment,and the difference was significant( P ＜0. 05 ); Before and after treatment the SAS and SDS score of the control group had no significant difference(P ＞0. 05). Compared with the control group,the excellence and total effective rate increased significantly in the observation group(P ＞ 0. 05). Conclusion Adjunctive therapy with deanxit could improve the anxiety and athymia,and elevate clinical curative effect.

Clinical analysis of dompeird one combined with flupentixol, melitracen (deanxit) and alprazolam in the treatment of functional dyspepsia / 中国医师杂志

Objective To evaluate the efficacy and safety of domperidone combined with flupentix-ol,melitracen ( deanxit ) and alprazolam in the treatment of functional dyspepsia .Methods One hundred and sixty patients with functional dyspepsia were randomly divided into the treatment group ( n =80 ) and the control group ( n =80 ) .The treatment group was given domperidone combined with flupentixol , meli- tracen (deanxit) and alprazolam, and the control group was only given domperidone for 4 weeks.The im-provement of clinical symptoms such as stomach burn ,early enough, abdominal distension, sour regurgita -tion and eructation were evaluated by clinical symptom score .Results Compared with patients in the con-trol group, the rate of marked improvement and rates of improvement for patients in the treatment group were all better ( P <0.01).Furthermore, the adverse reaction is light .Conclusion The application of domp-eridone combined with flupentixol, melitracen ( deanxit ) and alprazolam is quite effective in treating patients with FD.

Controlled Clinical Trials on Treatment of Depression with Tuina or Deanxit / 针灸推拿医学（英文版）

Objective: To observe the clinical efficacy of tuina in treating depression.Method: Eighty depression cases that conformed to the inclusive criteria were randomized into tuina and Deanxit group, with 40 cases in each group. Tuina manipulations were adopted for cases in the tuina group, 30 min for each treatment. While 2 Deanxit tablets were adopted for cases in the Deanxit group, twice a day. The clinical efficacy of the two groups was evaluated by using Hamilton Rating Scale for Depression (HAMD) before treatment and the 2nd, 4th and 6thweeks after. In addition, the Treatment Emergent Symptom Scale (TESS) was adopted to evaluate the adverse reactions in the two groups. Result: Both tuina and Deanxit can help to relieve the symptoms of depression patients. The effective rate of tuina and Deanxit were 72.5% and 70.0% respectively. However, there were no adverse reactions in tuina group, while 12.5% of adverse reaction rate occurred in the Deanxit group. Conclusion: Tuina can definitely benefit patients with depression and cause no adverse reactions.

Effect of Deanxit in the Treatment of Post-stroke Depression and Anxiety / 药物流行病学杂志

Objective:To investigate the clinical effects of deanxit in the treatment of post-stroke depression and anxiety.Method:65 stroke patients with depressive and anxious disorder were randomly divided into two groups which were treated with deanxit(as deanxit group) and without deanxit(as controlled group) respectively.SDS and SAS scales were used to evaluate the changes of clinical symptoms.Result:The scores of SDS and SAS scales in the deanxit group after 2 weeks'treatment were 36.37?7.07 and 32.91?5.28,which were significantly lower than those of the controlled group (P

Effects of Deanxit Associated with Illumination on the Depressed Patients with Chronic Pain / 中国康复理论与实践

@#ObjectiveTo study the effects of Deanxit associated with illumination on the depressed patients with chronic pain in open psychology ward in general hospitals.Methods41 patients were assigned into two groups:study group included 21 patients,who received the treatment of Deanxit(1 mg/d),even more with the treatment of illumination;control group included 20 patients,who only received the treatment of Deanxit(1 mg/d).Assessments of the efficacy were performed with Beck depression inventory(BDI) and Hamilton depression scale(HAMD) before and in the 2nd,4th,8th week during treatment.In addition,Symptom Checklist-90(SCL-90) was also used before and after treatment,as well as six month after discharge.ResultsThe efficacy was consistent with study group's superiority versus control group.ConclusionThe treatment consisting of Deanxit associated with illumination is effective on depression and helpful to prevent relapsing.